1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bone Therapeutics: Helping Bone Regenerate, And To Knit Together

 
• By John Davis

Executive Interview: A raft of clinical trial results are expected in the second half of 2018 for Bone Therapeutics' regenerative cell therapy approach to hip osteonecrosis and delayed-union fractures.  

Bone Therapeutics chairman Jean Stephenne (on the left) and CEO Thomas Lienard
Bone Therapeutics's chairman Jean Stephenne (L) and CEO Thomas Lienard • Source: Bone Therapeutics

Bone Therapeutics SA is expecting clinical trial results from two studies in the second half of 2018 involving its novel regenerative cell therapies for bone conditions, conclusions of an interim analysis of a Phase III study of its autologous cell therapy, PREOB, in patients with hip osteonecrosis, and final results from a Phase IIA study of its allogeneic cell product, ALLOB, in patients with delayed-union fractures, company executives told Scrip in a recent interview.

Earlier this year, Bone Therapeutics raised €20m in a convertible bond that increased its cash runway to the third quarter...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

More from R&D

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.